Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05332054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05332054 · ClinicalTrials.gov record · last posted 2026-03-12

Long-Term Follow-up Study

Study acronym: LTFS
StatusEnrolling by Invitation
PhaseNot specified
Started2022-03-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2022-04-14; most recent amendment 2026-03-11. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT05332054
Lead Sponsor Caribou Biosciences, Inc.
Conditions Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy +2 more
Enrollment 150 participants
Start Date 2022-03-16
Primary Completion 2041-12 (estimated)
Study Completion 2041-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-12